Research programme: phosphodiesterase IV inhibitors - CJ Corporation

Drug Profile

Research programme: phosphodiesterase IV inhibitors - CJ Corporation

Alternative Names: PDE4 inhibitors research programme - CJ Corporation

Latest Information Update: 07 Dec 2006

Price : $50

At a glance

  • Originator CJ Corporation
  • Class
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 23 Dec 2002 Cheil Jedang is now called CJ Corporation
  • 23 Jun 2000 Preclinical development for Asthma in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top